$CYTK News
Last published 2d ago
- 2d agoCYTKCytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026GlobeNewswireNew Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten
- 2d agoCYTKCytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026GlobeNewswireNew Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced
- 1w agoCYTKCYTOKINETICS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCYTKCytokinetics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireMYQORZO® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in
- 1w agoCYTKCytokinetics to Participate in November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor
- 1w agoCYTKCytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one
- 3w agoCYTKCytokinetics to Announce Third Quarter Results on November 4, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time.
- 3w agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of
- 3w agoCYTKCytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the
- 1mo agoCYTKCytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026GlobeNewswireAdditional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE
- 1mo agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of
- 1mo agoCYTKMorgan Stanley 24th Annual Global Healthcare Conference - CYTOKINETICS INCEarnings Call TranscriptsGreat. Thank you, everyone, for joining. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morgans
- 1mo agoCYTKCytokinetics Announces Call for Proposals for Ninth Annual Communications Grant ProgramGlobeNewswireProgram Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026
- 2mo agoCYTKCytokinetics to Participate in September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor
- 2mo agoCYTKCytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026GlobeNewswireAdditional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across
- 2mo agoCYTKCytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of MedicineGlobeNewswireACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New
- 2mo agoCYTKCytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026GlobeNewswireHot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to
- 2mo agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares of
- 3mo agoCYTKCytokinetics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireMYQORZO® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026
- 3mo agoCYTKCytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and WalesGlobeNewswireAuthorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,
- 3mo agoCYTKCytokinetics to Announce Second Quarter Results on August 6, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time.
- 3mo agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of
- 4mo agoCYTKCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026GlobeNewswireHot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to
- 4mo agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common
- 5mo agoCYTKCytokinetics Announces Call for Proposals for Annual Corporate Giving ProgramGlobeNewswireProgram to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,
- 5mo agoCYTKCytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in GermanyGlobeNewswireEuropean Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the first commercial European
- 5mo agoCYTKCytokinetics to Participate in June Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences
- 5mo agoCYTKCytokinetics to Hold Annual Meeting of StockholdersGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific
- 5mo agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807 shares of common
- 6mo agoCYTKCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)GlobeNewswireThird Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today
- 6mo agoCYTKCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in a fireside chat at the 2026 RBC
- 6mo agoCYTKCytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026GlobeNewswireMultinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the
- 6mo agoCYTKCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 MillionGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including
- 6mo agoCYTKCytokinetics Announces Pricing of Upsized Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price
- 6mo agoCYTKQ1 2026 Earnings - CYTOKINETICS INCEarnings Call TranscriptsHello, everyone. Thank you for standing by and welcome to the Cytokinetics Q1 2026 Earnings Conference Call. This call is being recorded and all participants are in a listen-only mode. There will be no question and answe
- 6mo agoCYTKCytokinetics Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its
- 6mo agoCYTKCytokinetics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireU.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise
- 6mo agoCYTKACACIA-HCM Topline Results - CYTOKINETICS INCEarnings Call TranscriptsThank you for standing by and welcome to Cytokinetics conference call to discuss the top-line results of Acacia HCM. This call is being recorded and all participants are in a listen-only mode. After the speaker's remarks
- 6mo agoCYTKCytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic CardiomyopathyGlobeNewswireTrial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key Secondary Endpoints Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern
- 6mo agoCYTKCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026GlobeNewswireCompany to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will report
- 6mo agoCYTKCytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 CongressGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place
- 6mo agoCYTKCytokinetics to Announce First Quarter Results on May 5, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time.
- 6mo agoCYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49,358 shares of
- 7mo agoCYTKCytokinetics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at
- 8mo agoCYTKCytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & ExpoGlobeNewswireNew Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,
- 8mo agoCYTKCytokinetics to Participate in March Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor
- 8mo agoCYTKQ4 2025 Earnings - CYTOKINETICS INCEarnings Call TranscriptsThank you for standing by and welcome to the Cytokinetics 4th Quarter 2025 Earnings Call. This call is being recorded and all participants are in a listen-only mode. After the speaker's remarks, we will open the call to
- 8mo agoCYTKCytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireMYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM
- 8mo agoCYTKCytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyGlobeNewswireEuropean Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated
- 9mo agoCYTKCytokinetics to Announce Fourth Quarter Results on February 24, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern